Moderna Yönetim

Yönetim kriter kontrolleri 2/4

Moderna CEO'su Stephane Bancel, Oct2011 tarihinde atandı, in görev süresi 11.42 yıldır. in toplam yıllık tazminatı $ 18.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.5% maaş ve 94.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.44% ine doğrudan sahiptir ve bu hisseler CHF 2.68B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 8.8 yıldır.

Anahtar bilgiler

Stephane Bancel

İcra Kurulu Başkanı

US$18.2m

Toplam tazminat

CEO maaş yüzdesi	5.5%
CEO görev süresi	11.4yrs
CEO sahipliği	5.4%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	8.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Stephane Bancel'un ücretlendirmesi Moderna'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2022	n/a	n/a	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Tazminat ve Piyasa: Stephane 'nin toplam tazminatı ($USD 18.16M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.73M ).

Tazminat ve Kazançlar: Stephane şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Stephane Bancel (49 yo)

11.4yrs

Görev süresi

US$18,155,739

Tazminat

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% CHF 278.7m
Stephane Bancel	CEO & Director	11.4yrs	US$18.16m	5.44% CHF 2.7b
Stephen Hoge	President	no data	US$7.80m	0.46% CHF 227.6m
Shannon Klinger	Chief Legal Officer & Corporate Secretary	1.8yrs	US$11.76m	0.0015% CHF 743.3k
Juan Andres	President of Strategic Partnerships & Enterprise Expansion	5.6yrs	US$6.60m	0.0033% CHF 1.6m
James Mock	Chief Financial Officer	less than a year	Veri yok	Veri yok
Jerh Collins	Chief Technical Operations & Quality Officer	less than a year	Veri yok	Veri yok
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	6.4yrs	Veri yok	Veri yok
Brad Miller	Chief Information Officer	less than a year	Veri yok	Veri yok
Lavina Talukdar	Senior VP & Head of Investor Relations	3.9yrs	Veri yok	Veri yok
Colleen Hussey	Senior Director of Corporate Communications	no data	Veri yok	Veri yok
Tracey Franklin	Chief Human Resources Officer	3.4yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 0QF 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% CHF 278.7m
Stephane Bancel	CEO & Director	12yrs	US$18.16m	5.44% CHF 2.7b
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Elizabeth Tallett	Independent Director	2.7yrs	US$594.93k	0.00018% CHF 88.6k
Robert Langer	Independent Non Executive Director & Member of Scientific Advisory Board	12.3yrs	US$586.80k	2.98% CHF 1.5b
Scott Canute	Member of Technology Advisory Board	8.8yrs	Veri yok	Veri yok
Elizabeth Nabel	Independent Director	2yrs	US$633.39k	0.00018% CHF 88.6k
Fred Regnier	Member of Technology Advisory Board	8.8yrs	Veri yok	Veri yok
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jack Szostak	Chairman of Scientific Advisory Board	8.8yrs	Veri yok	Veri yok
John Aunins	Member of Technology Advisory Board	8.8yrs	Veri yok	Veri yok
Stephen Berenson	Independent Non Executive Director	5.4yrs	US$591.43k	0.0054% CHF 2.6m

8.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0QF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

Moderna Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna, Inc. Announces Board Changes

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Recent updates

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş